Tranaxemic Acid Drug Study
Generic name: tranexamic acid
General
Pronunciation:
tran-ex-AM-ikAS -id
Trade Name(s)
• Cyklokapron
• Lysteda
Pregnancy Category
Category B
Ther. class. hemostatic agents
Pharm. class. antifibrinolytics plasminogen inactivators
Indications
• IV: Prevention or reduction of hemorrhage during and following dental surgery in hemophiliacs.
• PO: Treatment of cyclic heavy menstrual bleeding.
Action
Inhibits activation of plasminogen, thereby preventing the conversion of plasminogen to plasmin.
Therapeutic Effect(s):
• Decreased bleeding following dental surgery in hemophiliacs.
• Reduced need for replacement therapy.
• Reduced menstrual blood loss.
Pharmacokinetics
Absorption: 100% bioavailable with IV administration; 45% bioavailability after oral administration.
Distribution: Penetrates readily into joint fluid and synovial membranes.
Metabolism and Excretion: 95% excreted unchanged in urine.
Half-life: 2 hr (IV) (↑ in renal impairment); 11 hr (PO).
TIME/ACTION PROFILE (blood levels)
ROUTE
ONSET
PEAK
DURATION
IV
unknown unknown 7–8 hr
PO
unknown
2.5 hr unknown Contraindication/Precautions
Contraindicated in:
• Hypersensitivity;
• Thromboembolic disorders (current, history of, or at risk for);
• Acquired defective color vision (IV);
• Subarachnoid hemorrhage.
Use Cautiously in:
• Renal impairment (↑ dosing interval);
• Hematuria originating in the upper urinary tract;
• Conditions associated with ↑ thrombus formation;
• Use of hormonal contraceptives (PO);
• OB: Lactation: Pedi: Safety not established.
Adverse Reactions/Side Effects
CNS: SEIZURES, headache, dizziness.
EENT: visual abnormalities.
CV: hypotension, thromboembolism, thrombosis.
GI: diarrhea, nausea, vomiting.
MS: pain.
Misc: PO—ANAPHYLAXIS .
*CAPITALS indicates life-threatening.
*italic indicates most frequent.
Interactions
Drug-Drug
• Concurrent use of clotting factor complexes may ↑ the risk of thrombotic
General
Pronunciation:
tran-ex-AM-ikAS -id
Trade Name(s)
• Cyklokapron
• Lysteda
Pregnancy Category
Category B
Ther. class. hemostatic agents
Pharm. class. antifibrinolytics plasminogen inactivators
Indications
• IV: Prevention or reduction of hemorrhage during and following dental surgery in hemophiliacs.
• PO: Treatment of cyclic heavy menstrual bleeding.
Action
Inhibits activation of plasminogen, thereby preventing the conversion of plasminogen to plasmin.
Therapeutic Effect(s):
• Decreased bleeding following dental surgery in hemophiliacs.
• Reduced need for replacement therapy.
• Reduced menstrual blood loss.
Pharmacokinetics
Absorption: 100% bioavailable with IV administration; 45% bioavailability after oral administration.
Distribution: Penetrates readily into joint fluid and synovial membranes.
Metabolism and Excretion: 95% excreted unchanged in urine.
Half-life: 2 hr (IV) (↑ in renal impairment); 11 hr (PO).
TIME/ACTION PROFILE (blood levels)
ROUTE
ONSET
PEAK
DURATION
IV
unknown unknown 7–8 hr
PO
unknown
2.5 hr unknown Contraindication/Precautions
Contraindicated in:
• Hypersensitivity;
• Thromboembolic disorders (current, history of, or at risk for);
• Acquired defective color vision (IV);
• Subarachnoid hemorrhage.
Use Cautiously in:
• Renal impairment (↑ dosing interval);
• Hematuria originating in the upper urinary tract;
• Conditions associated with ↑ thrombus formation;
• Use of hormonal contraceptives (PO);
• OB: Lactation: Pedi: Safety not established.
Adverse Reactions/Side Effects
CNS: SEIZURES, headache, dizziness.
EENT: visual abnormalities.
CV: hypotension, thromboembolism, thrombosis.
GI: diarrhea, nausea, vomiting.
MS: pain.
Misc: PO—ANAPHYLAXIS .
*CAPITALS indicates life-threatening.
*italic indicates most frequent.
Interactions
Drug-Drug
• Concurrent use of clotting factor complexes may ↑ the risk of thrombotic